Skip to the content
Please enable JavaScript in your browser to complete this form.
Evaluation Survey
Thank you for participating in the
MARWALL Asia: Opportunity and Challenges in R/R ALL
webinar. We hope that you found it useful. Your feedback is very important to us and we would appreciate it if you could complete this brief survey.
*
indicates required fields.
1) Please rate the following aspects of the meeting:
Overall sessions
Session 1: Immunotherapy in R/R ALL: where are we now?
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Session 2: Insights and updates on bridging to transplantation in R/R ALL
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Keynote presentations
How I use inotuzumab ozogamicin in treating patients with R/R ALL - Daniel DeAngelo (USA)
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Strategies on improving outcomes with inotuzumab ozogamicin: Focus on HSCT - David Marks (UK)
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Meeting organization
Program date and duration
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Platform functionality
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Duration of panel discussions
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
Overall meeting
*
Excellent
Very Good
Good
Satisfactory
Poor
Excellent
Item #1 Excellent
Very Good
Item #1 Very Good
Good
Item #1 Good
Satisfactory
Item #1 Satisfactory
Poor
Item #1 Poor
2) The webinar advanced my knowledge of immunotherapy and its role in optimizing outcomes for patients with R/R ALL
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
3) How likely would you participate in a similar event organized by us in the future (1 = very unlikely, 5 = very likely)?
*
1
2
3
4
5
1
Item #1 1
2
Item #1 2
3
Item #1 3
4
Item #1 4
5
Item #1 5
4) What other related topics would you like covered in future meetings?
5) Do you have any additional feedback/comments?
Submit
EM-CHN-ino-0008